Cargando…

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

AIMS: Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence‐based clinical guidelines, is a key reason for uncontrolled hyperglycaemia in patients with type 2 diabetes. The aims of this systematic review were to identify how therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khunti, Kamlesh, Gomes, Marilia B., Pocock, Stuart, Shestakova, Marina V., Pintat, Stéphane, Fenici, Peter, Hammar, Niklas, Medina, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813232/ https://www.ncbi.nlm.nih.gov/pubmed/28834075 http://dx.doi.org/10.1111/dom.13088

Ejemplares similares

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
por: Khunti, Sachin, et al.
Publicado: (2019)

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019)

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
por: Wilding, John, et al.
Publicado: (2018)

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study
por: Patel, Krishna K., et al.
Publicado: (2020)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Type 2 diabetes and heart failure: insights from the global DISCOVER study
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Socioeconomic Factors Associated With Glycemic Measurement and Poor HbA1c Control in People With Type 2 Diabetes: The Global DISCOVER Study
por: Gomes, Marília B., et al.
Publicado: (2022)

Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
por: Bongaerts, Brenda, et al.
Publicado: (2021)

Overcoming Therapeutic Inertia as the Achilles’ Heel for Improving Suboptimal Diabetes Care: An Integrative Review
por: Chew, Boon-How, et al.
Publicado: (2023)

Treatment patterns and glycated haemoglobin levels over 36 months in individuals with type 2 diabetes initiating second‐line glucose‐lowering therapy: The global DISCOVER study
por: Charbonnel, Bernard H., et al.
Publicado: (2022)

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people
por: Khunti, Kamlesh, et al.
Publicado: (2013)

Is therapeutic inertia present in hyperglycaemia, hypertension and hypercholesterolaemia management among adults with type 2 diabetes in three health clinics in Malaysia? a retrospective cohort study
por: Chew, Boon-How, et al.
Publicado: (2021)

Prediction of type 2 diabetes risk in people with non-diabetic hyperglycaemia: model derivation and validation using UK primary care data
por: Coles, Briana, et al.
Publicado: (2020)

Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association
por: Gabbay, Robert A., et al.
Publicado: (2020)

Nonadherence, Clinical Inertia, or Therapeutic Inertia?
por: Allen, J. Daniel, et al.
Publicado: (2009)

Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin
por: Khunti, K., et al.
Publicado: (2016)

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
por: Caspard, Herve, et al.
Publicado: (2017)

Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review
por: Gavin, James R., et al.
Publicado: (2023)

Overcoming Therapeutic Inertia in Type 2 Diabetes Care—Timing, Context, and Appropriateness of Treatment Intensification
por: McCoy, Rozalina G., et al.
Publicado: (2021)

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®)
por: Arnold, Suzanne V., et al.
Publicado: (2017)

Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting
por: Orozco‐Beltrán, Domingo, et al.
Publicado: (2021)

Therapeutic Inertia is a Problem for All of Us
por: Brunton, Stephen
Publicado: (2019)

Fructosamine Is a Useful Indicator of Hyperglycaemia and Glucose Control in Clinical and Epidemiological Studies – Cross-Sectional and Longitudinal Experience from the AMORIS Cohort
por: Malmström, Håkan, et al.
Publicado: (2014)

The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes
por: Levy, Brian L, et al.
Publicado: (2016)

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review
por: Okemah, Jennifer, et al.
Publicado: (2018)

Hyperglycaemia, glycosuria and ketonuria may not be diabetes.
por: Gray, J., et al.
Publicado: (2003)

Cigarette Smoking and Hyperglycaemia in Diabetic Patients
por: Sari, Mutiara Indah, et al.
Publicado: (2018)

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
por: Gerich, J E
Publicado: (2010)

Gravitation and inertia
por: Ciufolini, Ignazio, et al.
Publicado: (1995)

Cellular inertia
por: Ishiwata, Ryosuke, et al.
Publicado: (2021)

Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care
por: Saposnik, Gustavo, et al.
Publicado: (2018)

Clinical Inertia in Individualising Care for Diabetes: Is There Time to do More in Type 2 Diabetes?
por: Strain, William David, et al.
Publicado: (2014)

Clinical Inertia in Type 2 Diabetes Patients in Primary Health Care Clinics in Central Bosnia
por: Marjanović, Marijan, et al.
Publicado: (2018)

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

Breaking Therapeutic Inertia in Type 2 Diabetes: Active Detection of In-Patient Cases Allows Improvement of Metabolic Control at Midterm
por: Lucas Martín, Anna M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s1vbags2fd3a4nc35t65vbtlot